3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Ovarian Neoplasms
60
Breast Neoplasms
21
Neoplasms
19
Fallopian Tube Neoplasms
16
Prostatic Neoplasms
15
Neoplasm Metastasis
9
Pancreatic Neoplasms
8
Endometrial Neoplasms
8
Glioblastoma
7
Triple Negative Breast Neoplasms
6
Lung Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Small Cell Lung Carcinoma
4
Glioma
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Mesothelioma
3
Melanoma
3
Head and Neck Neoplasms
3
Cystadenocarcinoma, Serous
3
Cholangiocarcinoma
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Stomach Neoplasms
2
Solid Tumor
2
Sarcoma
2
Prostatic Neoplasms, Castration-Resistant
2
Ovarian Diseases
2
Mesothelioma, Malignant
2
Interventions
Doxorubicin
18
Ifosfamide
13
Radiotherapy
8
Paclitaxel
7
pazopanib
6
pembrolizumab
4
Gemcitabine
4
Filgrastim
4
Chemotherapy, Adjuvant
4
Bevacizumab
4
spartalizumab
3
durvalumab
3
Sorafenib
3
Propranolol
3
Nivolumab
3
Ipilimumab
3
Imatinib Mesylate
3
Etoposide
3
Epirubicin
3
Docetaxel
3
Carboplatin
3
trebananib
2
regorafenib
2
cixutumumab
2
cemiplimab
2
carotuximab
2
brostallicin
2
belinostat
2
balstilimab
2
Vincristine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hemangiosarcoma
×
niraparib
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled